한글목차

세계의 건초염용 경구약 시장의 미래는 병원·클리닉, 약국, 온라인 쇼핑몰 시장에서의 기회로 유망시되고 있습니다. 세계의 건초염용 경구약 시장은 2025-2031년에 CAGR 3.5%로 성장할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 신체 활동 및 스포츠 부상 증가, 건초염 및 관련 질환의 유병률 증가, 경구용 의약품의 발전입니다.

• Lucintel의 예측에 따르면 유형별로는 NSAIDs가 환자들에게 접근성이 좋고 비용 효율성이 높아 예측 기간 중 높은 성장세를 보일 것으로 예상했습니다.
• 용도별로는 약국이 비스테로이드성 항염증약, 진통제 등 다양한 유형의 경구용 의약품을 제공하고 있으므로 약국이 높은 성장세를 보일 것으로 예측됩니다.
• 지역별로는 북미가 운동질환 유병률이 높고 의료 접근성이 높아 예측 기간 중 가장 높은 성장세를 보일 것으로 예측됩니다.

건초염 경구용 의약품 시장의 새로운 동향

건초염 경구용 의약품 시장은 보다 효과적이고 환자 중심적인 치료로의 전환을 반영하여 몇 가지 중요한 추세를 목격하고 있습니다.

• 생물제제로의 전환: 생물제제를 통한 경구 치료는 만성 건초염의 중요한 치료법으로 부상하고 있습니다. TNF 억제제와 같은 이러한 약물은 근본적인 염증 과정에 표적화하여 작용하므로 기존의 비스테로이드성 항염증약나 코르티코스테로이드에 비해 부작용이 적고, 장기적인 치료 효과를 기대할 수 있습니다.
• 맞춤형 의료: 유전적, 분자적 요인에 기반한 맞춤형 치료 계획이 인기를 끌고 있습니다. 환자 고유의 염증 지표와 유전적 소인을 분석함으로써 의사는 가장 적합한 내복약을 선택해 치료 결과를 개선하고 부작용을 줄일 수 있습니다.
• 병용요법: 경구용 코르티코스테로이드 및 비스테로이드성 항염증약와 생물제제 및 면역조절제를 포함한 다른 유형의 약물을 병용하는 것이 저항성 및 만성 건초염을 관리하기 위한 일반적인 접근법이 되고 있습니다. 이러한 추세는 보다 맞춤화되고 효과적인 치료 요법으로 이어지고 있습니다.
• 일반의약품의 선택권 확대: 건초염에 대한 일반의약품이 더욱 광범위하게 사용되고 있으며, 환자들이 진통 및 항염증 치료에 쉽게 접근할 수 있게 되었습니다. 이러한 일반의약품(OTC)품은 일반적으로 비스테로이드성 항염증약(NSAIDs)를 기반으로 하며, 편의성이 높지만 오남용을 방지하기 위해 엄격하게 규제되고 있습니다.
• 자연요법 및 약초요법: 기존 치료의 보조 및 대체약으로 천연약과 약초 경구약에 대한 관심이 높아지고 있습니다. 심황, 생강 및 기타 항염증 허브는 건초염의 종합적인 치료의 일환으로 특히 인도와 중국 등지에서 인기를 끌고 있습니다.

이러한 추세는 생물제제에서 OTC 의약품에 이르기까지 환자에게 치료 옵션을 제공하고, 개인 맞춤형 치료와 자연요법의 기술 혁신을 촉진함으로써 시장을 재구성하고 있습니다.

건초염 경구용 의약품 시장의 최근 동향

몇 가지 주요 발전이 건초염 경구용 의약품 시장을 발전시키고 있으며, 새로운 치료법, 제형 및 접근법이 임상에 도입되고 있습니다.

• 새로운 생물제제의 승인: TNF 억제제를 포함한 생물제제의 승인과 치료 요법에 대한 통합은 만성 건초염 치료에 큰 변화를 가져왔습니다. 이들 치료제는 기존 코르티코스테로이드에 비해 부작용이 적고, 표적화된 치료 옵션을 제공합니다.
• NSAID 제제의 발전: 효능을 유지하면서 소화기 부작용을 최소화하기 위해 보다 안전한 경구용 NSAID 제제가 새롭게 개발되고 있습니다. 이러한 기술 혁신은 환자의 순응도와 건초염의 전반적인 치료 결과를 개선하는 데 매우 중요합니다.
• 맞춤의료 접근법: 유전체 및 분자 의학의 발달로 건초염에 대한 맞춤 치료 전략의 개발이 촉진되고 있습니다. 유전자 및 염증 프로파일에 따라 경구용 약물 요법을 조정함으로써 치료 효과를 높이고 부작용의 위험을 최소화할 수 있습니다.
• 일반의약품에 대한 관심 증가: 비스테로이드성 항염증약 외용제, 항염증약 내복약 등 건초염에 대한 일반의약품의 활용도가 높아지고 있습니다. 이러한 추세는 환자에게 병상 관리의 자율성을 부여하는 동시에 의료비용을 절감하는 효과를 가져오고 있습니다.
• 천연 항염증약의 등장: 커큐민이나 생강과 같은 자연 요법을 경구 치료 옵션에 도입하는 사례가 증가하고 있습니다. 이러한 대체요법은 건초염에 따른 염증과 통증 관리에 효과적이라는 연구 결과가 속속 발표되고 있습니다.

이러한 개발로 인해 치료 옵션의 가용성, 효과, 다양성이 향상되어 건초염 환자의 다양한 요구를 충족시킬 수 있게 되었습니다.

목차

제1장 개요

제2장 시장 개요

• 배경과 분류
• 공급망

제3장 시장 동향과 예측 분석

• 업계 촉진요인과 과제
• PESTLE 분석
• 특허 분석
• 규제 환경

제4장 세계의 건초염용 경구약 시장 : 유형별

• 개요
• 매력 분석 : 유형별
• NSAID : 동향과 예측(2019-2031년)
• 건이완제, 혈행 촉진제, 진통제 : 동향과 예측(2019-2031년)

제5장 세계의 건초염용 경구약 시장 : 용도별

• 개요
• 매력 분석 : 용도별
• 병원·클리닉 : 동향과 예측(2019-2031년)
• 약국 : 동향과 예측(2019-2031년)
• 온라인 쇼핑몰 : 동향과 예측(2019-2031년)

제6장 지역 분석

• 개요
• 세계의 건초염용 경구약 시장 : 지역별

제7장 북미의 건초염용 경구약 시장

• 개요
• 북미의 건초염용 경구약 시장 : 유형별
• 북미의 건초염용 경구약 시장 : 용도별
• 미국의 건초염용 경구약 시장
• 멕시코의 건초염용 경구약 시장
• 캐나다의 건초염용 경구약 시장

제8장 유럽의 건초염용 경구약 시장

• 개요
• 유럽의 건초염용 경구약 시장 : 유형별
• 유럽의 건초염용 경구약 시장 : 용도별
• 독일의 건초염용 경구약 시장
• 프랑스의 건초염용 경구약 시장
• 스페인의 건초염용 경구약 시장
• 이탈리아의 건초염용 경구약 시장
• 영국의 건초염용 경구약 시장

제9장 아시아태평양의 건초염용 경구약 시장

• 개요
• 아시아태평양의 건초염용 경구약 시장 : 유형별
• 아시아태평양의 건초염용 경구약 시장 : 용도별
• 일본의 건초염용 경구약 시장
• 인도의 건초염용 경구약 시장
• 중국의 건초염용 경구약 시장
• 한국의 건초염용 경구약 시장
• 인도네시아의 건초염용 경구약 시장

제10장 기타 지역(ROW)의 건초염용 경구약 시장

• 개요
• ROW의 건초염용 경구약 시장 : 유형별
• ROW의 건초염용 경구약 시장 : 용도별
• 중동의 건초염용 경구약 시장
• 남미의 건초염용 경구약 시장
• 아프리카의 건초염용 경구약 시장

제11장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석
  • 경쟁 기업 간 경쟁 관계
  • 바이어의 교섭력
  • 공급업체의 교섭력
  • 대체품의 위협
  • 신규 진출업체의 위협
• 시장 점유율 분석

제12장 기회와 전략 분석

• 밸류체인 분석
• 성장 기회 분석
  • 성장 기회 : 유형별
  • 성장 기회 : 용도별
• 세계의 건초염용 경구약 시장의 새로운 동향
• 전략 분석
  • 신제품 개발
  • 인증·라이선싱
  • 기업인수합병(M&A), 계약, 제휴, 합병사업

제13장 밸류체인에서 주요 기업의 개요

• 경쟁 분석
• Sanofi S.A.
• Novartis AG
• GSK
• Pfizer
• Teva
• Sunflower Pharmaceutical
• Baiyunshan Pharmaceutical
• Lingrui Pharmaceutical
• Bayer
• Yunnan Baiyao

제14장 부록

• 도표 리스트
• 표 리스트
• 분석 방법
• 면책사항
• 저작권
• 약어와 기술 단위
• Lucintel 소개
• 문의

영문목차

The future of the global oral medicine for tenosynovitis market looks promising with opportunities in the hospital clinic, pharmacy, and online shopping mall markets. The global oral medicine for tenosynovitis market is expected to grow with a CAGR of 3.5% from 2025 to 2031. The major drivers for this market are the rise in physical activity and sports injuries, the rising prevalence of tenosynovitis and related disorders, and the advancements in oral medications.

• Lucintel forecasts that, within the type category, NSAIDs is expected to witness higher growth over the forecast period due to easily accessible for patients and cost-effective.
• Within the application category, pharmacy is expected to witness the higher growth due to pharmacies offer a wide range of oral medications, including NSAIDs, analgesics.
• In terms of region, North America is expected to witness the highest growth over the forecast period due to high prevalence of musculoskeletal disorders, advanced healthcare access.

Emerging Trends in the Oral Medicine for Tenosynovitis Market

The oral medicine for tenosynovitis market is witnessing several key trends, reflecting shifts toward more effective and patient-centered approaches to treatment.

• Shift to Biologic Therapies: Biologic oral therapies are emerging as an important treatment for chronic tenosynovitis. These medications, such as TNF inhibitors, offer targeted action against the underlying inflammatory processes, providing better long-term relief and fewer side effects compared to traditional NSAIDs and corticosteroids.
• Personalized Medicine: Tailored treatment plans based on genetic and molecular factors are gaining traction. By analyzing a patient's specific inflammatory markers or genetic predispositions, doctors can select the most appropriate oral medications, improving outcomes and reducing side effects.
• Combination Therapies: Combining oral corticosteroids or NSAIDs with other classes of drugs, including biologics or immune modulators, is becoming a common approach for managing resistant or chronic cases of tenosynovitis. This trend is leading to more customized and effective treatment regimens.
• Growth in Over-the-Counter Options: Over-the-counter (OTC) oral medications for tenosynovitis are becoming more widely available, providing patients with easier access to pain relief and anti-inflammatory treatments. These OTC options are typically based on NSAIDs and offer convenience, although they are being closely regulated to prevent misuse.
• Natural and Herbal Treatments: There is increasing interest in natural and herbal oral medicines as adjuncts or alternatives to conventional treatments. Turmeric, ginger, and other anti-inflammatory herbs are gaining popularity as part of integrated care for tenosynovitis, particularly in regions like India and China.

These trends are reshaping the market by offering patients more treatment options, from biologics to OTC medications, and driving innovation in personalized and natural therapies.

Recent Developments in the Oral Medicine for Tenosynovitis Market

Several key developments are advancing the oral medicine for tenosynovitis market, with new therapies, formulations, and approaches making their way into clinical practice.

• Approval of New Biologic Agents: The approval and integration of biologic oral medications, including TNF inhibitors, into treatment regimens have marked a significant shift in the management of chronic tenosynovitis. These therapies offer targeted treatment options with fewer side effects compared to traditional corticosteroids.
• Advancements in NSAID Formulations: New, safer oral NSAID formulations are being developed to minimize gastrointestinal side effects while maintaining efficacy. These innovations are critical in improving patient compliance and overall treatment outcomes for tenosynovitis.
• Personalized Medicine Approaches: Advances in genomics and molecular medicine have facilitated the development of personalized treatment strategies for tenosynovitis. By tailoring oral drug regimens based on genetic or inflammatory profiles, treatments are becoming more effective and minimizing the risk of adverse effects.
• Increased Focus on OTC Medications: The availability of over-the-counter medications for tenosynovitis, such as topical NSAIDs and oral anti-inflammatory drugs, is growing. This trend is giving patients more autonomy in managing their condition while reducing healthcare costs.
• Emergence of Natural Anti-inflammatory Therapies: The integration of natural remedies like curcumin and ginger into oral treatment options is on the rise. These alternatives are increasingly being researched for their efficacy in managing inflammation and pain associated with tenosynovitis.

These developments are improving the availability, efficacy, and variety of treatment options, helping to meet the diverse needs of patients with tenosynovitis.

Strategic Growth Opportunities in the Oral Medicine for Tenosynovitis Market

The oral medicine for tenosynovitis market presents several strategic growth opportunities, particularly in novel treatments and market expansion.

• Expansion in Emerging Markets: The rising prevalence of musculoskeletal disorders in emerging markets, particularly in regions like India and China, presents a significant opportunity for oral medicines. As healthcare access improves, the demand for effective and affordable treatments is expected to grow.
• Development of Combination Therapies: The market for combination oral therapies, such as NSAIDs combined with biologics or immune-modulating drugs, is a promising growth area. These treatments offer enhanced effectiveness for patients with resistant or chronic tenosynovitis.
• Focus on Precision Medicine: There is an increasing opportunity for growth in the precision medicine segment, where treatment is tailored to the individual's genetic profile. This personalized approach is expected to drive more targeted and effective treatments for tenosynovitis.
• Natural and Alternative Therapies: The growing demand for natural and herbal treatments presents a unique growth opportunity. Manufacturers can explore the development of oral medicines based on proven anti-inflammatory herbs, tapping into consumer preferences for natural solutions.
• Enhanced Over-the-Counter Offerings: The growing acceptance of over-the-counter oral medicines for musculoskeletal conditions offers a promising opportunity for market growth. Manufacturers can capitalize on this demand by providing safe and effective OTC options for managing tenosynovitis.

These opportunities are expanding the market by offering a variety of treatment options that cater to diverse patient preferences and needs, from biologics to natural therapies.

Oral Medicine for Tenosynovitis Market Driver and Challenges

The oral medicine for tenosynovitis market is influenced by a variety of technological, economic, and regulatory factors, which shape both growth and challenges.

The factors responsible for driving the Oral Medicine for Tenosynovitis market include:

1. Rising Incidence of Musculoskeletal Disorders: The increasing prevalence of conditions like tenosynovitis, especially in aging populations and those with repetitive strain injuries, is a key driver for the demand for oral medicines.

2. Advancements in Drug Formulations: The development of safer, more effective oral formulations of NSAIDs, corticosteroids, and biologics is driving growth in the market, improving patient compliance and outcomes.

3. Demand for Personalized Treatments: The shift toward personalized medicine is enabling more effective and targeted therapies, enhancing treatment outcomes for patients with tenosynovitis and contributing to market growth.

4. Increased Access to Healthcare: Improved access to healthcare, particularly in emerging markets, is fueling demand for oral medications, as patients seek effective and affordable treatments for musculoskeletal conditions.

5. Cost-Effectiveness of Oral Treatments: Oral medications are often more cost-effective compared to injectable or surgical treatments, making them a preferred choice for patients, especially in low-to-middle-income countries.

Challenges in the Oral Medicine for Tenosynovitis market are:

1. Risk of Side Effects: The potential for side effects, such as gastrointestinal issues from NSAIDs and long-term complications from corticosteroids, remains a significant challenge in the market.

2. Regulatory Hurdles: Stricter regulations and lengthy approval processes for new oral medicines can delay market entry and limit the pace of innovation, hindering growth.

3. Patient Compliance: While oral medications are generally more convenient, patient adherence to long-term treatment regimens can still be a challenge, especially for chronic cases of tenosynovitis.

These drivers and challenges influence the overall growth trajectory of the oral medicine market, highlighting the need for innovative, patient-centered treatments while addressing concerns related to side effects and regulatory approvals.

List of Oral Medicine for Tenosynovitis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies oral medicine for tenosynovitis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the oral medicine for tenosynovitis companies profiled in this report include-

• Sanofi S.A.
• Novartis AG
• GSK
• Pfizer
• Teva
• Sunflower Pharmaceutical
• Baiyunshan Pharmaceutical
• Lingrui Pharmaceutical
• Bayer
• Yunnan Baiyao

Oral Medicine for Tenosynovitis Market by Segment

The study includes a forecast for the global oral medicine for tenosynovitis market by type, application, and region.

Oral Medicine for Tenosynovitis Market by Type [Value from 2019 to 2031]:

• NSAIDs
• Relaxing Tendons, Activating Blood Circulation And Analgesic

Oral Medicine for Tenosynovitis Market by Application [Value from 2019 to 2031]:

• Hospital Clinic
• Pharmacy
• Online Shopping Mall

Oral Medicine for Tenosynovitis Market by Region [Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Oral Medicine for Tenosynovitis Market

The oral medicine for tenosynovitis market, a condition involving inflammation of the tendons and their surrounding sheaths, has seen several developments worldwide. These advancements reflect an increased understanding of the disease, improved oral treatment options, and growing demand for effective therapies to manage inflammation and pain. The global market for oral medications used in treating tenosynovitis is driven by factors such as better drug formulations, patient-centered treatments, and the rising prevalence of musculoskeletal disorders. Key regions such as the United States, China, Germany, India, and Japan are contributing to these advancements with innovative therapies and improving healthcare access.

• United States: In the U.S., there has been significant development in the use of oral corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) for the management of tenosynovitis. Additionally, biologic therapies are gaining attention for patients with chronic or resistant cases. Recent research focuses on the effectiveness of combination therapies and long-term treatment strategies, leading to better clinical outcomes. The U.S. also leads in the approval of new oral medications targeting inflammation and pain, driving market growth.
• China: The oral medicine for tenosynovitis market in China is experiencing growth, particularly with the increasing awareness of musculoskeletal conditions. China is expanding its use of oral NSAIDs and corticosteroids, though there is a growing push for alternative treatments like natural anti-inflammatory agents. Due to the rising aging population and prevalence of repetitive stress injuries, the demand for effective oral treatments is expected to continue to increase, leading to innovations in both traditional and modern therapeutic approaches.
• Germany: Germany has a robust healthcare system that emphasizes both conventional treatments and innovative therapies. The market for oral medicine targeting tenosynovitis is advancing with the growing use of biologics and disease-modifying drugs. Germany is also a key player in research focused on oral formulations of corticosteroids and NSAIDs that offer targeted relief. The regulatory environment in Germany supports the development of novel treatments, creating a favorable market for new oral drugs.
• India: In India, tenosynovitis treatment is increasingly being managed with oral NSAIDs, corticosteroids, and other medications that address inflammation. The market is expanding due to a rising incidence of musculoskeletal disorders, particularly in the working population. Additionally, cost-effective oral therapies are gaining popularity in India, with a significant focus on improving access to medications. There is also interest in exploring traditional herbal medicines as adjuncts to conventional treatments.
• Japan: Japan is focusing on precision medicine in the treatment of tenosynovitis, with the growing use of oral biologic agents and advanced NSAIDs. The country has a high demand for effective oral treatments, especially among older populations, who are more prone to tendonitis and related conditions. Japan's healthcare system supports the development and use of new oral therapies that are both effective and safe, ensuring rapid adoption of novel treatments in clinical settings.

Features of the Global Oral Medicine for Tenosynovitis Market

• Market Size Estimates: Oral medicine for tenosynovitis market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
• Segmentation Analysis: Oral medicine for tenosynovitis market size by type, application, and region in terms of value ($B).
• Regional Analysis: Oral medicine for tenosynovitis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the oral medicine for tenosynovitis market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the oral medicine for tenosynovitis market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the oral medicine for tenosynovitis market by type (NSAIDs and relaxing tendons, activating blood circulation and analgesic), application (hospital clinic, pharmacy, and online shopping mall), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Oral Medicine for Tenosynovitis Market by Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Type
• 4.3 NSAIDs: Trends and Forecast (2019-2031)
• 4.4 Relaxing Tendons, Activating Blood Circulation and Analgesic: Trends and Forecast (2019-2031)

5. Global Oral Medicine for Tenosynovitis Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Hospital Clinic: Trends and Forecast (2019-2031)
• 5.4 Pharmacy: Trends and Forecast (2019-2031)
• 5.5 Online Shopping Mall: Trends and Forecast (2019-2031)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Oral Medicine for Tenosynovitis Market by Region

7. North American Oral Medicine for Tenosynovitis Market

• 7.1 Overview
• 7.2 North American Oral Medicine for Tenosynovitis Market by type
• 7.3 North American Oral Medicine for Tenosynovitis Market by application
• 7.4 United States Oral Medicine for Tenosynovitis Market
• 7.5 Mexican Oral Medicine for Tenosynovitis Market
• 7.6 Canadian Oral Medicine for Tenosynovitis Market

8. European Oral Medicine for Tenosynovitis Market

• 8.1 Overview
• 8.2 European Oral Medicine for Tenosynovitis Market by type
• 8.3 European Oral Medicine for Tenosynovitis Market by application
• 8.4 German Oral Medicine for Tenosynovitis Market
• 8.5 French Oral Medicine for Tenosynovitis Market
• 8.6 Spanish Oral Medicine for Tenosynovitis Market
• 8.7 Italian Oral Medicine for Tenosynovitis Market
• 8.8 United Kingdom Oral Medicine for Tenosynovitis Market

9. APAC Oral Medicine for Tenosynovitis Market

• 9.1 Overview
• 9.2 APAC Oral Medicine for Tenosynovitis Market by type
• 9.3 APAC Oral Medicine for Tenosynovitis Market by application
• 9.4 Japanese Oral Medicine for Tenosynovitis Market
• 9.5 Indian Oral Medicine for Tenosynovitis Market
• 9.6 Chinese Oral Medicine for Tenosynovitis Market
• 9.7 South Korean Oral Medicine for Tenosynovitis Market
• 9.8 Indonesian Oral Medicine for Tenosynovitis Market

10. ROW Oral Medicine for Tenosynovitis Market

• 10.1 Overview
• 10.2 ROW Oral Medicine for Tenosynovitis Market by type
• 10.3 ROW Oral Medicine for Tenosynovitis Market by application
• 10.4 Middle Eastern Oral Medicine for Tenosynovitis Market
• 10.5 South American Oral Medicine for Tenosynovitis Market
• 10.6 African Oral Medicine for Tenosynovitis Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Type
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Oral Medicine for Tenosynovitis Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 Sanofi S.A.
  • Company Overview
  • Oral Medicine for Tenosynovitis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Novartis AG
  • Company Overview
  • Oral Medicine for Tenosynovitis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 GSK
  • Company Overview
  • Oral Medicine for Tenosynovitis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Pfizer
  • Company Overview
  • Oral Medicine for Tenosynovitis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Teva
  • Company Overview
  • Oral Medicine for Tenosynovitis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 Sunflower Pharmaceutical
  • Company Overview
  • Oral Medicine for Tenosynovitis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Baiyunshan Pharmaceutical
  • Company Overview
  • Oral Medicine for Tenosynovitis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Lingrui Pharmaceutical
  • Company Overview
  • Oral Medicine for Tenosynovitis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 Bayer
  • Company Overview
  • Oral Medicine for Tenosynovitis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Yunnan Baiyao
  • Company Overview
  • Oral Medicine for Tenosynovitis Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us